Please wait, loading...
Please wait, loading...
ROD TURNER
Acting CEO
Rod TURNER is the founder and CEO of Manhattan Street Capital, the #1 Growth Capital service for mature startups and mid sized companies to raise capital using Regulation A+. Turner has played a key role in building successful companies including Symantec/Norton (SYMC), Ashton Tate, MicroPort, Knowledge Adventure and more. He is an experienced investor who has built a Venture Capital business (Irvine Ventures) and has made angel and mezzanine investments in companies such as Bloom, Amyris (AMRS), Ask Jeeves and eASIC
–
ERGİN YILDIZ
Founder & CFO
Ergin YILDIZ has been a finance Professional for the last 30 years in various Banks and Financial Institutions based in Luxembourg, Istanbul, Bucharest and Malta. He was the CFO of Silicon Valley based Regulon Inc. specialized on Liposomal Oncology Drugs
Ergin has worked with many financial institutions like CITIBANK, UBS or UBS as well as well known Audit, Rating and consultancy companies like E&Y, KPMG and JCR in his Professional life for fundraising and corporate financing activities of pharmaceutical industry
–
Prof. TAMARA MINKO
Chief Scientific Adviser
Prof. Tamara MINKO PhD. is a Distinguished Professor and Chair of the Department of Pharmaceutics at Rutgers, The State University of New Jersey. She is also a member of the Cancer Institute of New Jersey, Environmental and Occupational Health Sciences Institute. Her current research interests include drug delivery; biopharmaceutics; nanotechnology; molecular targeting; antisense oligonucleotides, siRNA and peptide delivery; mechanisms of multidrug resistance; intracellular fate and molecular mechanisms of action of anticancer drugs; bioimaging; macromolecular therapeutics; preclinical evaluation of new therapeutics; modulation of cell death mechanisms during hypoxia
Professor Minko is author and co-author of more than 400 publications.
–
Nassos ALEVIZOPOULOS
Member Of Scientific Board
Nassos Alevizopoulos (PhD) is a Brunner Prize recipient for the excellence of his PhD in cancer signal transduction, earned from the University of Lausanne in 1996. He also holds an MBA from the same Institution. In the last 20+ years he has held positions in small biotechs as well as multinational companies in Greece, Switzerland, Germany, and the USA, cutting across the whole value chain of biopharmaceutical drug development, with a focus on cancer and rare diseases. He is a technical expert reviewer of several European grants, such as Eureka-Eurostars, European Research Council and Horizon 2020. Among other achievements, he successfully designed, outsourced and managed preclinical and clinical research drug development projects in oncology and led teams to achieve an Orphan Drug Designation from EMA for Pancreatic Cancer for Liposomal Cisplatin in 2007